Drugs / Neoantigen Reactive T Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06432075 | Jun 2024 → Jan 2026 overdue | gastric cancer | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03171220 | Jun 2017 → Dec 2019 | cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen Reactive T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06432075 ↗ |
| Known as | NRTs | “neoantigen reactive T cells(NRTs) will be generated in the laboratory” NCT03171220 ↗1“Neoantigen Reactive T Cells(NRTs)” NCT06432075 ↗ |
| Modality | Cell therapy | “Our center has successfully established a new method for preparing personalized neoantigen reactive T cells(NRTS) for adoptive cell therapy(ACT).” NCT03171220 ↗ |
| Route | Intravenous | “Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.” NCT03171220 ↗ |